TP53 and cancer: This phenomenon has been demonstrated in a wide range of cancers, where p53 has been restored (see Martins et al.,35 Ventura et al.36 and Xue et al.37) and supports the implications of our study that targeting Mdmx is a valid approach for treating BrCas harboring wt p53.